You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Contact a GSK Sales Representative

Chat with Medical Information

Image of ARNUITY ELLIPTA

SYNFLORIX

Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed 1

SYNFLORIX

SYNFLORIX helps protect children against pneumococcal disease.

SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against diseases caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross-reactive 19A: 1

  • invasive disease (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia)
  • pneumonia
  • acute otitis media (AOM)

SYNFLORIX is part of the Quebec Immunization Program.2

 

Dosing and Administration

Dosing Schedule and Administration Information

See the SYNFLORIX dosing schedule for infants and children up to 5 years of age.

Review details about co-administration with other vaccines.

Dosing and Administration

Efficacy data

Demonstrated efficacy in two large-scale clinical trials 1

Learn more about the demonstrated efficacy of SYNFLORIX

Disease overview

Pneumococcal disease

Learn more about the clinical features, incidence, and distribution of invasive disease caused by specific Streptococcus pneumoniae serotypes in children up to 5 years of age.

Learn About the Disease

Indications and clinical use:

SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against diseases caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross-reactive 19A: 1

  • invasive disease (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia)
  • pneumonia
  • acute otitis media (AOM)

Not for use in adults.

Geriatrics (>65 years of age): Not studied.

Relevant warnings and precautions:

  • Intended for use in children up to 5 years of age; children <5 years should receive appropriate-for-age vaccination series
  • In acute, severe, febrile illness, postpone administration
  • Should not be administered intravascularly or intradermally
  • Will not protect against pneumococcal serogroups or serotypes that are not included in the vaccine, except the cross-reactive serotype 19A
  • Potential risk of apnoea and need for respiratory monitoring for 48-72 hours when administering the primary immunization series to very premature infants and particularly for those with a previous history of respiratory immaturity
  • Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection
  • Should be given with caution to individuals with thrombocytopenia or any coagulation disorder
  • As with any vaccine, a protective immune response may not be elicited in all vaccines

For more information:

Please consult the Product Monograph at
http://ca.gsk.com/media/591956/synflorix.pdf for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.

The Product Monograph is also available by calling 1-800-387-7374.

References:

  1. Synflorix Product Monograph. GlaxoSmithKline Inc. August 31, 2018.
  2. Santé et Services Sociaux Québec. Protocole d’immunisation du Québec (PIQ). Available at: http://www.msss.gouv.qc.ca/professionnels/vaccination/protocole-d-immunisation-du-quebec-piq/. Accessed May 2, 2018.

Trademarks are owned by or licensed to the GSK group of companies.

© 2019 GSK group of companies or its licensor.

Français